Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Edelman c/o Abbott Diagnostics

Events

18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

Antibodies to Carbamylated Proteins Provide Insight into Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 05 Feb 2013
Print article
Detection of antibodies to carbamylated proteins (anti-CarP) is an important advance in the diagnosis of Rheumatoid Arthritis (RA).

A study published in 2012 by a team at Leiden University Medical Center (LUMC; Leiden, The Netherlands) in Proceedings of the National Academy of Sciences of the United States of America (PNAS) showed that Immunoglobulin G (IgG) and IgA antibodies recognizing carbamylated antigens were present in about 50% of RA patients. Anti-CarP antibodies recognize homocitrulline and are therefore distinct from anticitrullinated protein antibodies (ACPA), including anti-cyclic citrullinated peptide (anti-CCP), a biomarker commonly used to diagnose RA. Anti-CarP IgG and IgA were detected in 16% and 30% of ACPA negative RA patients respectively. Additionally, anti-CarP antibodies were shown to be predictive of a more severe course of disease as measured by radiological progression in ACPA negative RA patients.

LUMC and Inova (San Diego, CA, USA) have announced the completion of an exclusive, worldwide license agreement for technology developed at LUMC to detect antibodies to carbamylated proteins (anti-CarP). "The detection of autoantibodies in sera of RA patients has provided important insight into the processes that initiate and drive RA. Since anti-CarP antibodies can also be detected in a subgroup of patients for whom so far no serological markers were available we believe this may provide new insight into the pathogenesis of RA,"said Dr. Leendert Trouw, assistant professor at LUMC.

Prof. Tom Huizinga, head of the department of Rheumatology at LUMC added "With new treatment options at hand it is now possible to apply early and aggressive treatment. Understanding which patients would benefit most from such an intervention is important to maximize efficiency, and detection of anti-CarP antibodies may identify such patients."

The LUMC is part of the Dutch Federation of University Medical Centers (NFU). The NFU is a collaboration of the eight University Medical Centers of The Netherlands.

Related Links:

Leiden University Medical Center
Inova



Print article
Micromedic Technologies

Channels

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.